吉西他滨
医学
肿瘤科
养生
放射治疗
内科学
临床终点
化疗
临床研究阶段
胰腺导管腺癌
胰腺癌
临床试验
生物标志物
联合疗法
生存分析
化疗方案
原发性肿瘤
存活率
总体生存率
癌症
腺癌
肿瘤微环境
联合化疗
无进展生存期
外科
放化疗
作者
Ke Cheng,Chenyan Zhang,Jiaxin Liu,Huanji Xu,Jitao Zhou,Zixing Huang,Qiting Wu,Yi Zhang,Ping Chen,Weikang Shao,Zhiping Li,Ye Chen,Gang Zhao,Yi Cheng,Yu Yang,Xin You,Wenhao Guo,Xiaofen Li,Wanting Hou,Xiaoying Li
标识
DOI:10.1158/1078-0432.ccr-26-1824
摘要
PURPOSE: The prognosis for metastatic pancreatic ductal adenocarcinoma (mPDAC) remains dismal. In this multicenter, single-arm, phase II study, we evaluated the combination of serplulimab, gemcitabine plus nab-paclitaxel, and radiotherapy (ICSBR regimen) as first-line treatment for mPDAC patients (ChiCTR2300073237). METHODS: Patients with mPDAC were enrolled in the first-line setting. The treatment regimen consisted of serplulimab and gemcitabine plus nab-paclitaxel administered in 21-day cycles, combined with stereotactic body radiotherapy directed at the primary or metastatic sites during cycle 2. Additionally, comprehensive biomarker analysis was conducted. The primary endpoint was the 6-month progression-free survival (PFS) rate, with a predefined target of 60%. RESULT: Forty-six patients received at least one dose of treatment. The 6-month PFS rate was 78.3% (95% CI, 67.2%-91.1%). The median PFS and overall survival (OS) were 8.5 months (95% CI, 7.3-12.0 months) and 14.0 months (95% CI, 12.0 months-not reached), respectively. The objective response rate was 73.9% (95% CI, 58.9%-85.7%). The combination treatment was well tolerated, and no treatment-related deaths or unexpected safety signals were observed. Notably, patients with baseline ctDNA negativity achieved a better survival. Moreover, tumor microenvironment (TME) analysis revealed that baseline fibroblast activation protein-positive cancer-associated fibroblast and T-cell proportions in tumor tissue correlated with clinical outcomes, with distinct spatial distribution and interaction tendencies observed among patients with different responses. CONCLUSION: Overall, the ICSBR regimen demonstrated a promising survival benefit as first-line treatment for mPDAC. Furthermore, ctDNA status and TME analysis highlighted potential markers for guiding precision treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI